

Terence C Chua

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11982071/publications.pdf>

Version: 2024-02-01

99
papers

5,838
citations

94269

37
h-index

74018

75
g-index

100
all docs

100
docs citations

100
times ranked

5506
citing authors

#	ARTICLE	IF	CITATIONS
1	Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 2449-2456.	0.8	873
2	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. <i>Journal of Clinical Oncology</i> , 2009, 27, 6237-6242.	0.8	598
3	Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?. <i>Annals of Surgery</i> , 2009, 249, 900-907.	2.1	479
4	Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review. <i>Current Opinion in Neurology</i> , 2008, 21, 83-92.	1.8	251
5	Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of This Novel Treatment Option. <i>Annals of Surgical Oncology</i> , 2010, 17, 484-491.	0.7	182
6	Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1637-1645.	1.2	169
7	Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—A systematic review. <i>International Journal of Cancer</i> , 2012, 130, 2845-2856.	2.3	157
8	Extended Pancreaticoduodenectomy with Vascular Resection for Pancreatic Cancer: A Systematic Review. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1442-1452.	0.9	135
9	Factors Predicting Response and Survival After Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver Metastases. <i>Annals of Surgery</i> , 2010, 251, 910-916.	2.1	134
10	A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. <i>Cancer</i> , 2011, 117, 1855-1863.	2.0	129
11	Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2010, 17, 492-501.	0.7	127
12	Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2012, 23, 96-105.	0.2	122
13	Surgical resection of hepatic metastases from neuroendocrine neoplasms: A systematic review. <i>Surgical Oncology</i> , 2012, 21, e131-e141.	0.8	116
14	Long-Term Survival in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: 10 Years of Experience from a Single Institution. <i>Annals of Surgical Oncology</i> , 2009, 16, 1903-1911.	0.7	109
15	Influence of Modern Systemic Therapies as Adjunct to Cytoreduction and Perioperative Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 1560-1567.	0.7	87
16	Morbidity and Mortality Outcomes of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy at a Single Tertiary Institution. <i>Annals of Surgery</i> , 2010, 251, 101-106.	2.1	74
17	Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: The Australian experience. <i>Journal of Surgical Oncology</i> , 2009, 99, 109-113.	0.8	72
18	Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei. <i>Annals of Surgical Oncology</i> , 2010, 17, 1291-1301.	0.7	72

#	ARTICLE	IF	CITATIONS
19	Diffuse malignant peritoneal mesothelioma – An update on treatment. <i>Cancer Treatment Reviews</i> , 2012, 38, 605-612.	3.4	71
20	Impact of the Peritoneal Surface Disease Severity Score on Survival in Patients with Colorectal Cancer Peritoneal Carcinomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2010, 17, 1330-1336.	0.7	70
21	Diffusion Tensor Imaging of the Posterior Cingulate is a Useful Biomarker of Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 602-613.	0.6	68
22	Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 166-174.	1.9	68
23	Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases – A systematic review. <i>Surgical Oncology</i> , 2012, 21, 299-308.	0.8	68
24	Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. <i>Surgical Oncology</i> , 2012, 21, 95-101.	0.8	64
25	Summary of current therapeutic options for peritoneal metastases from colorectal cancer. <i>Journal of Surgical Oncology</i> , 2013, 107, 566-573.	0.8	59
26	Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases – A systematic review. <i>European Journal of Cancer</i> , 2012, 48, 1757-1765.	1.3	58
27	Inflammatory Markers in Blood and Serum Tumor Markers Predict Survival in Patients With Epithelial Appendiceal Neoplasms Undergoing Surgical Cytoreduction and Intraperitoneal Chemotherapy. <i>Annals of Surgery</i> , 2012, 256, 342-349.	2.1	56
28	MUC1 as a Potential Target in Anticancer Therapies. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 108-118.	0.6	54
29	Clinicopathologic and Treatment-Related Factors Influencing Recurrence and Survival after Hepatic Resection of Intrahepatic Cholangiocarcinoma: A 19-Year Experience from an Established Australian Hepatobiliary Unit. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1128-1138.	0.9	53
30	Determining the Association Between Preoperative Computed Tomography Findings and Postoperative Outcomes After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei. <i>Annals of Surgical Oncology</i> , 2011, 18, 1582-1589.	0.7	51
31	Evaluation of the Cost-Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (Peritonectomy) at the St George Hospital Peritoneal Surface Malignancy Program. <i>Annals of Surgery</i> , 2010, 251, 323-329.	2.1	50
32	Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 865-873.	1.2	48
33	Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. <i>Cancer</i> , 2010, 116, 2106-2114.	2.0	45
34	Summary outcomes of two-stage resection for advanced colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 2013, 107, 211-216.	0.8	43
35	Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. <i>International Journal of Clinical Oncology</i> , 2013, 18, 439-446.	1.0	43
36	Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome. <i>International Journal of Colorectal Disease</i> , 2012, 27, 381-389.	1.0	42

#	ARTICLE	IF	CITATIONS
37	A formulation for <i>in situ</i> lysis of mucin secreted in pseudomyxoma peritonei. International Journal of Cancer, 2014, 134, 478-486.	2.3	41
38	Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Management and Research, 2012, 4, 413.	0.9	39
39	Histological Subtype Remains a Significant Prognostic Factor for Survival Outcomes in Patients With Appendiceal Mucinous Neoplasm With Peritoneal Dissemination. Diseases of the Colon and Rectum, 2017, 60, 360-367.	0.7	37
40	Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. Journal of Surgical Oncology, 2013, 108, 81-88.	0.8	36
41	Peritoneal metastases of lower gastrointestinal tract origin: a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1899-1908.	1.2	35
42	Development of a Bayesian Belief Network Model for Personalized Prognostic Risk Assessment in Colon Carcinomatosis. American Surgeon, 2011, 77, 221-230.	0.4	31
43	Heat Sink Phenomenon of Bipolar and Monopolar Radiofrequency Ablation Observed Using Polypropylene Tubes for Vessel Simulation. Surgical Innovation, 2014, 21, 269-276.	0.4	30
44	Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Canadian Journal of Surgery, 2009, 52, 59-64.	0.5	30
45	Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Journal of Surgical Oncology, 2009, 100, 139-143.	0.8	29
46	Upfront Compared to Delayed Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Is Associated With Considerably Lower Perioperative Morbidity and Recurrence Rate. Annals of Surgery, 2011, 253, 769-773.	2.1	28
47	Radioembolisation with ⁹⁰ Y microspheres: An effective treatment modality for unresectable liver metastases. Journal of Medical Imaging and Radiation Oncology, 2013, 57, 72-80.	0.9	28
48	Prognostic Significance of Ki67 Expression in Malignant Peritoneal Mesothelioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 388-394.	0.6	25
49	Intra-arterial iodine-131-iodine for unresectable hepatocellular carcinoma. Cancer, 2010, 116, 4069-4077.	2.0	24
50	Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. American Journal of Surgery, 2011, 201, 149-156.	0.9	24
51	Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation. Journal of the American College of Surgeons, 2010, 211, 526-535.	0.2	23
52	Impacts of low peritoneal cancer index on the survival outcomes of patient with peritoneal carcinomatosis of colorectal origin. International Journal of Surgery, 2015, 23, 181-185.	1.1	23
53	Significance of Lymph Node Metastasis in Patients with Colorectal Cancer Peritoneal Carcinomatosis. World Journal of Surgery, 2009, 33, 1488-1494.	0.8	22
54	Impact of Prior Hepatectomy on the Safety and Efficacy of Radioembolization With Yttrium-90 Microspheres for Patients With Unresectable Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 454-460.	0.6	22

#	ARTICLE	IF	CITATIONS
55	Impacts of peritoneal cancer index on the survival outcomes of patients with colorectal peritoneal carcinomatosis. <i>International Journal of Surgery</i> , 2016, 32, 65-70.	1.1	21
56	Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results. <i>Surgical Oncology</i> , 2011, 20, e161-e168.	0.8	20
57	Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. <i>Gynecologic Oncology</i> , 2009, 114, 137-139.	0.6	19
58	Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. <i>Journal of Surgical Oncology</i> , 2012, 105, 342-350.	0.8	19
59	Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP). <i>International Journal of Medical Sciences</i> , 2017, 14, 18-28.	1.1	19
60	Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei. <i>Journal of Surgical Oncology</i> , 2009, 99, 292-295.	0.8	18
61	Outcomes of Single-Centre Experience of Hepatic Resection and Cryoablation of Sarcoma Liver Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 317-320.	0.6	17
62	Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. <i>International Journal of Clinical Oncology</i> , 2011, 16, 125-132.	1.0	16
63	Optimizing the Surgical Effort in Patients With Advanced Neuroendocrine Neoplasm Hepatic Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 439-445.	0.6	16
64	Surgical Cytoreduction and Survival in Appendiceal Cancer Peritoneal Carcinomatosis: An Evaluation of 46 Consecutive Patients. <i>Annals of Surgical Oncology</i> , 2011, 18, 1540-1546.	0.7	15
65	Establishing evidence for change in ovarian cancer surgery – Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis. <i>Gynecologic Oncology</i> , 2009, 115, 166-168.	0.6	14
66	Hepatic Resection for Transplantable Hepatocellular Carcinoma for Patients Within Milan and UCSF Criteria. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 141-145.	0.6	14
67	Surgery for colorectal peritoneal carcinomatosis. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 277-285.	0.6	13
68	Peritoneal Mesothelioma. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 635-643.	0.6	13
69	Palliative Effects of an Incomplete Cytoreduction Combined With Perioperative Intraperitoneal Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 568-571.	0.6	12
70	Impacts of Preoperative Serum Albumin Level on Outcomes of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2016, 23, 2411-2418.	0.7	12
71	Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. <i>Anticancer Research</i> , 2010, 30, 3005-7.	0.5	11
72	Trends in surgical oncology research in Australia during the period 1998–2009—a bibliometric review. <i>Journal of Surgical Oncology</i> , 2011, 104, 216-219.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Intraoperative macroscopic tumour consistency is associated with overall survival after cytoreductive surgery and intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases: A retrospective observational study. <i>American Journal of Surgery</i> , 2019, 217, 704-712.	0.9	10
74	Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma. <i>Lung Cancer</i> , 2009, 66, 269-270.	0.9	9
75	Impact of Tumor Angiogenesis in Peritoneal Mesothelioma After Radical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. <i>Pathology and Oncology Research</i> , 2010, 16, 217-222.	0.9	9
76	Pseudomyxoma Peritonei: A Need to Establish Evidence-Based Standard of Care—Is This the Right Trial?. <i>Annals of Surgical Oncology</i> , 2009, 16, 2675-2677.	0.7	8
77	The St George Hospital Peritoneal Surface Malignancy Program — where are we now?. <i>ANZ Journal of Surgery</i> , 2009, 79, 416-418.	0.3	7
78	Ileocecal Intussusception Caused by an Appendiceal Neoplasm. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 867-868.	0.9	7
79	Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. <i>American Journal of Cancer Research</i> , 2013, 3, 411-23.	1.4	7
80	Cure for peritoneal metastases? An evidence-based review. <i>ANZ Journal of Surgery</i> , 2013, 83, 821-826.	0.3	6
81	Does the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?. <i>American Journal of Cancer Research</i> , 2013, 3, 312-22.	1.4	6
82	In vivo model of pseudomyxoma peritonei for novel candidate drug discovery. <i>Anticancer Research</i> , 2009, 29, 4051-5.	0.5	6
83	Second-line treatment of first relapse recurrent ovarian cancer. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2010, 50, 465-471.	0.4	5
84	Endovascular stenting of mesenterico-portal vein stenosis to reduce blood flow through venous collaterals prior to pancreatoduodenectomy. <i>Langenbeck's Archives of Surgery</i> , 2015, 400, 629-631.	0.8	5
85	Resectable Colorectal Liver Metastases: Optimal Sequencing of Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 496-498.	0.6	4
86	The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1037-1045.	1.2	4
87	New treatments and outcomes in peritoneal carcinomatosis. <i>Medical Journal of Australia</i> , 2009, 191, 3-4.	0.8	3
88	Colorectal Liver Metastases with Extrahepatic Disease—A New Criteria for Oncologic Resection?. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 502-504.	0.6	3
89	Pancreatic Metastasectomy—an Analysis of Survival Outcomes and Prognostic Factors. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1188-1193.	0.9	3
90	Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters. <i>American Journal of Cancer Research</i> , 2014, 4, 495-507.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Gastrointestinal oncological surgery in patients with metastatic cancer treated with angiogenesis inhibitors: safe or not?. ANZ Journal of Surgery, 2009, 79, 672-673.	0.3	2
92	Salvage cytoreduction for chemorefractory ovarian cancer with peritoneal carcinomatosis: A last chance or futile efforts?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2010, 50, 478-484.	0.4	2
93	Effect of Nonparallel Placement of In-Circle Bipolar Radiofrequency Ablation Probes on Volume of Tissue Ablated With Heat Sink. Surgical Innovation, 2015, 22, 223-234.	0.4	2
94	Repeat cytoreductive surgery with or without perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. American Journal of Surgery, 2017, 213, 1024-1030.	0.9	2
95	In Reply: Pseudomyxoma Peritonei: Debulk or Maximal Cytoreduction?. Annals of Surgical Oncology, 2011, 18, 284-285.	0.7	1
96	Treatments and Outcomes of Peritoneal Surface Tumors Through a Centralized National Service (United Kingdom). Diseases of the Colon and Rectum, 2010, 53, 1218-1219.	0.7	0
97	Surgical Management and Emerging Therapies to Prolong Survival in Metastatic Neuroendocrine Cancer. Annals of Surgical Oncology, 2011, 18, 222-223.	0.7	0
98	A commentary on concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. Journal of Human Genetics, 2014, 59, 176-177.	1.1	0
99	Hepatobiliary and Pancreatic: Dual system stenting of the biliary and porto-venous systems to palliate locoregional recurrence of hilar cholangiocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1239-1239.	1.4	0